Charles River Laboratories Intl. (CRL) Getting Somewhat Positive Press Coverage, Study Shows

News stories about Charles River Laboratories Intl. (NYSE:CRL) have been trending somewhat positive this week, according to Accern. Accern scores the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Charles River Laboratories Intl. earned a news impact score of 0.15 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 46.5611803415893 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:

Charles River Laboratories Intl. (NYSE:CRL) opened at $99.77 on Friday. The stock has a market cap of $4,725.31, a P/E ratio of 24.33, a P/E/G ratio of 1.46 and a beta of 0.74. Charles River Laboratories Intl. has a 1-year low of $81.81 and a 1-year high of $119.05. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88.

Charles River Laboratories Intl. (NYSE:CRL) last announced its earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.22 by $0.08. The company had revenue of $464.23 million during the quarter, compared to the consensus estimate of $458.93 million. Charles River Laboratories Intl. had a net margin of 10.72% and a return on equity of 26.58%. Charles River Laboratories Intl.’s revenue was up 9.0% compared to the same quarter last year. During the same period last year, the firm earned $1.18 earnings per share. equities analysts predict that Charles River Laboratories Intl. will post 5.14 EPS for the current year.

CRL has been the topic of several research reports. Credit Suisse Group reissued a “neutral” rating and set a $112.00 price objective (up from $95.00) on shares of Charles River Laboratories Intl. in a report on Monday, October 16th. Zacks Investment Research raised shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 price objective on the stock in a report on Tuesday, October 24th. Bank of America cut their price objective on shares of Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, November 10th. ValuEngine lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Finally, Robert W. Baird set a $117.00 price objective on shares of Charles River Laboratories Intl. and gave the company a “buy” rating in a report on Monday, November 13th. Eight analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $112.58.

In other Charles River Laboratories Intl. news, Director C Richard Reese sold 10,227 shares of the firm’s stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $102.40, for a total value of $1,047,244.80. Following the completion of the sale, the director now directly owns 51,444 shares in the company, valued at $5,267,865.60. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Chairman James C. Foster sold 4,967 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $109.44, for a total transaction of $543,588.48. Following the completion of the sale, the chairman now owns 329,928 shares of the company’s stock, valued at $36,107,320.32. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 195,673 shares of company stock valued at $2,644,046. 2.20% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: This article was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://stocknewstimes.com/2018/02/11/charles-river-laboratories-intl-crl-getting-somewhat-positive-press-coverage-study-shows.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply